Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.83 |
| ▸ | RAF1 | P04049 | 10/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | CSF1R | P07333 | 1/20 | 0.77 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | MET | P08581 | 1/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.77 |
| ▸ | KIT | P10721 | 1/20 | 0.77 |
| ▸ | BCR | P11274 | 1/20 | 0.77 |
| ▸ | FER | P16591 | 1/20 | 0.77 |
| ▸ | FLT1 | P17948 | 1/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012327 | 0.91 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1012434 | 0.88 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1012302 | 0.88 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL17053430 | 0.88 | BRAF (0.92) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1012794 | 0.87 | BRAF (0.93) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1013057 | 0.87 | BRAF (0.93) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29351427 | 0.87 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL1015932 | 0.87 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1012281 | 0.87 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29697285 | 0.87 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118234498-A | STING modulators, compositions, and methods of use thereof | 南佛罗里达大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-117897159-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117835976-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117120447-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116490507-A | Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer | 薛定谔公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |